抗性高血压的游戏变革:阿布罗西坦的兴起
1Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar.
Journal of cardiovascular pharmacology
|February 4, 2025
概括
一种新药,阿普罗西坦,为抗性高血压 (rHTN) 患者提供了希望. 这种双重内甲素受体抗剂有效降低血压,即使其他治疗方法失败.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 抗性高血压 (rHTN) 构成了重大的治疗挑战,往往对传统治疗无反应.
- 血压升高是全球发病率和死亡率的主要原因,需要新的管理策略.
- 内分泌素受体在调节血管度方面发挥着至关重要的作用.
研究的目的:
- 审查用于治疗抗性高血压的新型双内甲素受体对抗剂aprocitentan.
- 突出阿布罗西坦的作用机制,阻断内甲蛋白A (ETA) 和内甲蛋白B (ETB) 受体.
- 讨论临床疗效和近期FDA批准的aprocitentan.
主要方法:
- 对阿布罗西的临床前和临床数据的审查.
- 对PRECISION临床试验结果的分析.
- 检查药物的药理特征,作为一种双重内甲素受体对抗剂.
主要成果:
- 阿普罗西坦在患有rHTN的患者中显示出优越且持续的血压降低.
- 阿布罗西坦坦对ETA和ETB受体的双重阻断与显著的抗高血压作用有关.
- PRECISION试验证实了阿普罗西坦在抗高血压患者群体中的疗效.
结论:
- 阿普罗西坦在抗性高血压的药物治疗中取得了重大进展.
- 美国食品和药物管理局批准阿布罗西坦坦为难以治疗的高血压患者提供了一个新的,有效的选择.
- 用阿布罗西坦坦向内甲蛋白系统提供了一种有希望的方法来管理复杂的高血压病例.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
01:25Antihypertensive Drugs: Direct Renin Inhibitors
477
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
477
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
574
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
574
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
462
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
462
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
146
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
146